$ABBV presents updated data from the pivotal Ph3 MURANO trial of venetoclax in combo with rituximab in Patients with RR CLL ASH18 httpswww.prnewswire.comnewsreleasesabbviepresentsnewdatafromphase3muranotrialofvenclextavenclyxtovenetocl

$ABBV presents updated data from the pivotal Ph3 MURANO trial of venetoclax in combo with rituximab in Patients with R/R #CLL #ASH18 https://www.prnewswire.com/news-releases/abbvie-presents-new-data-from-phase-3-murano-trial-of-venclextavenclyxto-venetocl

18:13 EST 1 Dec 2018 | Odi Bruckman

$ABBV presents updated data from the pivotal Ph3 MURANO trial of venetoclax in combo with rituximab in Patients with R/R #CLL #ASH18 https://www.prnewswire.com/news-releases/abbvie-presents-new-data-from-phase-3-murano-trial-of-venclextavenclyxto-venetoclax-in-combination-with-rituximab-in-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia-who-completed-the-fixed-treatment-course-300758623.html …

More From BioPortfolio on "$ABBV presents updated data from the pivotal Ph3 MURANO trial of venetoclax in combo with rituximab in Patients with R/R #CLL #ASH18 https://www.prnewswire.com/news-releases/abbvie-presents-new-data-from-phase-3-murano-trial-of-venclextavenclyxto-venetocl"